MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Vaxcyte Inc

Closed

SectorHealthcare

34.41 3.8

Overview

Share price change

24h

Current

Min

32.29

Max

34.42

Key metrics

By Trading Economics

Income

-34M

-137M

EPS

-1.018

Employees

414

EBITDA

87M

-53M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+297.09% upside

Dividends

By Dow Jones

Next Earnings

6 maj 2025

Market Stats

By TradingEconomics

Market Cap

-6.3B

3.9B

Previous open

30.61

Previous close

34.41

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Vaxcyte Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

3 wrz 2024, 17:22 UTC

Top News

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

Peer Comparison

Price change

Vaxcyte Inc Forecast

Price Target

By TipRanks

297.09% upside

12 Months Forecast

Average 124.13 USD  297.09%

High 160 USD

Low 65 USD

Based on 11 Wall Street analysts offering 12 month price targets forVaxcyte Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

30.39 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.